Breaking News

Almac Doubles Development Capacity

January 14, 2013

Adds new non-GMP facility and two analytical labs

Almac has expanded its drug product pharmaceutical development services with a new non-GMP formulation development facility and two new analytical labs at its headquarters in Craigavon, doubling current capacity.
 
Although dedicated to non-GMP development, the facilities will employ all of the company’s technical capabilities of its existing GMP pharmaceutical development facility, including high levels of control over environmental conditions, as well as extending current capabilities in processing potent compounds with low OELs. The new non-GMP facility will primarily focus on lab-scale experiments, with batch sizes ranging from <1kg up to an expected maximum of 15 kg scale for most technologies.
 
John McQuaid, vice president of Technical Operations, said, “Our priority was to ensure we had good integration of all technologies in both the non-GMP and GMP facilities. Duplicating equipment trains means that we can conduct non-GMP work efficiently and then transfer rapidly to GMP manufacturing for clinical and registration batches. We are finding that demand for non-GMP process development work has increased as clients seek to better understand their processes in line with the principles of QbD. This type of work also creates large sample sets for analytical testing and multiple stability studies, which is why it was also important that we doubled our analytical capacity in parallel.”

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?